OTCMKTS:CYDY - CytoDyn Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.5050 -0.02 (-3.81 %)
(As of 01/16/2019 12:55 PM ET)
Previous Close$0.52
Today's Range$0.5050 - $0.52
52-Week Range$0.40 - $0.8360
Volume53,885 shs
Average Volume247,005 shs
Market Capitalization$155.25 million
P/E Ratio-1.74
Dividend YieldN/A
Beta0.41
CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company is based in Vancouver, Washington.

Receive CYDY News and Ratings via Email

Sign-up to receive the latest news and ratings for CYDY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CYDY
Previous SymbolNASDAQ:CYDY
CUSIPN/A
Phone360-980-8524

Debt

Current Ratio0.16
Quick Ratio0.16

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Book Value($0.03) per share
Price / Book-16.83

Profitability

Net Income$-50,140,000.00
Net MarginsN/A
Return on Assets-528.65%

Miscellaneous

Employees6
Market Cap$155.25 million
OptionableNot Optionable

CytoDyn (OTCMKTS:CYDY) Frequently Asked Questions

What is CytoDyn's stock symbol?

CytoDyn trades on the OTCMKTS under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn Inc (OTCMKTS:CYDY) posted its quarterly earnings results on Tuesday, October, 9th. The biotechnology company reported ($0.07) EPS for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.01. View CytoDyn's Earnings History.

What price target have analysts set for CYDY?

1 brokers have issued 12 month price targets for CytoDyn's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate CytoDyn's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 296.0% from the stock's current price. View Analyst Price Targets for CytoDyn.

What is the consensus analysts' recommendation for CytoDyn?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytoDyn in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CytoDyn.

Has CytoDyn been receiving favorable news coverage?

Media stories about CYDY stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CytoDyn earned a news sentiment score of 2.8 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an effect on the stock's share price in the near term.

Who are some of CytoDyn's key competitors?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:
  • Dr. Nader Z. Pourhassan, CEO, Pres & Director (Age 55)
  • Mr. Michael D. Mulholland, CFO, Treasurer & Corp. Sec. (Age 66)
  • Dr. Denis R. Burger, Scientific Consultant (Age 74)
  • Dr. Richard G. Pestell MBA. M.D., Ph.D., Chief Medical Officer & Director

How do I buy shares of CytoDyn?

Shares of CYDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CYDY stock can currently be purchased for approximately $0.5050.

How big of a company is CytoDyn?

CytoDyn has a market capitalization of $155.25 million. The biotechnology company earns $-50,140,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. CytoDyn employs 6 workers across the globe.

What is CytoDyn's official website?

The official website for CytoDyn is http://www.cytodyn.com.

How can I contact CytoDyn?

CytoDyn's mailing address is 1111 MAIN STREET SUITE 660, VANCOUVER WA, 98660. The biotechnology company can be reached via phone at 360-980-8524 or via email at [email protected]


MarketBeat Community Rating for CytoDyn (OTCMKTS CYDY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  215
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe CYDY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYDY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel